The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines

Table 1 Anti-proliferative activity (IC ₅₀ values) of 2-DG alone and in combination with platinum analogs and/or SB202190

Cell line	2-DG (mM)	Platinum (μM)	2-DG + Platinum			2-DG + 20uM SB202190 (mM)	Platinum + 20uM SB202190 (uM)	2-DG + 20 μM SB202190 + Platinum
Cell line	2-DG (mM)	Platinum (μM)	2-DG (mM)	Platinum (μM)	CI at IC50	2-DG + 20uM SB202190 (mM)	Platinum + 20uM SB202190 (uM)	2-DG (mM)	Platinum (μM)
MIA PaCa-2	1.45	3.37	0.95	0.48	0.796	0.48	19.72	0.24	0.12
BxPC-3	10.80	28.13	8.12	4.06	0.896	0.60	32.50	1.23	0.61
ASPC-1	11.47	>50	10.55	5.25	0.954	4.90	>50	5.77	2.88
OVCAR-3	3.39	6.93	3.39	1.69	1.243	3.9	26.45	4.1	2.05
HEY	10.17	32.90	9.88	4.94	1.122	2.63	50>	2.44	1.22
SK-OV-3	13.34	11.53	6.46	3.23	0.764	1.42	21.05	2.01	1.01

IC₅₀ values represent the level of drug that inhibited cell growth by 50% following 48 hours of treatment. Combination index (CI) values are defined as: <0.1 = very strong synergy, 0.1-0.3 = strong synergism, 0.3-0.7 = synergism, 0.7 – 0.85 = moderate synergism, 0.85-0.9 = slight synergism, 0.9-1.1 = nearly additive, 1.1-1.45 slight to moderate antagonism.